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Inﬂammation is widely known to play a key role in the development and progression of cardiovascular diseases. It is becoming
increasingly evident that obesity is linked to many proinﬂammatory and obesity-associated cardiovascular conditions (e.g.,
metabolic syndrome, acute coronary syndrome, and congestive heart failure). It has been observed that adipokines play an
increasingly large role in systemic and local inﬂammation. Therefore, adipose tissue may have a more important role than
previously thought in the pathogenesis of several disease types. This review explores the recently described role of adiponectin as
an immunomodulatory factor and how it intersects with the inﬂammation associated with both cardiovascular and autoimmune
pathologies.
1. Adiponectin
Adiponectin is a cytokine, “adipokine”, produced almost
exclusively in adipose tissue and is expressed at high levels by
lean, healthy individuals. However, it has been reported that
in pathological conditions such as coronary artery disease
(CAD), diabetes mellitus, and hypertension that adiponectin
levels decline [1–4]. The protein is present in human plasma
at a range between 3 and 30μg/mL; however, as body mass
increases,serumadiponectinlevelsdecrease[5,6].Thelarger
adipocytes found in obese subjects produce lower levels of
adiponectin but higher levels of proinﬂammatory cytokines,
such as TNFα [7]. The adiponectin monomer (30kDa) has a
structureconsisting of a globular head and a collagenous tail,
and this monomer is able to multimerize to form several sta-
blecomplexesoflow-,medium-,andhigh-molecularweight.
Adiponectin shares sequence homology with collagens VIII
and X as well as complement factor C1q. It has previously
been referred to as ACRP30 for adipose complement-related
peptide of 30kDa based upon its homology to C1q [8].
In addition to promoting adipocyte diﬀerentiation, PPAR-γ
agonists are known to increase adiponectin expression both
in vitro and in vivo [9]. Adiponectin inhibits the expression
of TNF-α in adipocytes, and both TNF-α and IL-6 inhibit
the production of adiponectin [9, 10]. Negative regulation
of adiponectin expression also results from hypoxia and
oxidative stress [11, 12]. It is interesting to hypothesize that
any or all of these factors could contribute to the vascular
breakdown that could create a vicious cycle of perpetual
inﬂammation in an obese state.
Given that the levels of adiponectin vary in diﬀerent
inﬂammatory diseases as discussed above, these data suggest
that the metabolic consequences observed in obesity may
be related to an imbalance of pro- and anti-inﬂammatory
cytokines.
Thus, adipokines contribute to the pathophysiology of
obesity-linked disorders through their ability to modify
proinﬂammatory and metabolic processes. Adipokines (such
as leptin, TNF-α, PAI type 1, IL-1β, IL-6, and IL-8) are
proinﬂammatory and increased in obesity [7]. In obese
subjects, adiponectin levels are decreased, and the ability of
adiponectin to inhibit the inﬂammatory processes is limited.
Low adiponectin levels are inversely related to high levels
of C-reactive protein (CRP) in patients with obesity, type 2
diabetes, and CAD [13–15].
Adiponectin also exerts anti-hypertrophic eﬀects and
protects against ischemia-reperfusion injury [16, 17].2 International Journal of Inﬂammation
Hypoadiponectinemia is a risk factor for patients with
obesity-related complications such as CAD and hyperten-
sion [1–3, 18]. Hypoadiponectinemia also contributes to
insulin resistance [19], impaired endothelium-dependent
vasodilatation, impaired ischemia-induced neovasculariza-
tion [20], salt-induced hypertension [21], and diastolic heart
failure [22]. Thus, adiponectin mediates protective eﬀects in
obesity-relatedmetabolicandvasculardiseasepresumablyby
its anti-inﬂammatory actions and protects the heart against
ischemia-reperfusion injury through its ability to suppress
myocardial inﬂammation and apoptosis [23]. Similarly, lack
of adiponectin exacerbates left ventricular hypertrophy and
systolic heart failure and increases mortality after experi-
mental aortic constriction [17, 24]. Hypoadiponectinemia
appears to promote hypertension progression [2], but the
mechanism by which this occurs is not entirely clear.
Adiponectinsupplementationsuppressestheprogression
of viral myocarditis in diabetic obese mice [25], inhibits
atherosclerosis progression in vitro by NF-κB inhibition
and phospho-Akt activation [26], and suppresses TNFα-
induced IκBα phosphorylation [27]. Interestingly, chronic
adiponectin overexpression increased subcutaneous fat mass
and protected against diet-induced insulin resistance [28].
2. Shifting Paradigm of Adiponectin Expression
inDisease
Obesity is considered a state of mild inﬂammation, and it
is well documented that increasing adiposity results in a
decrease in adiponectin production, thus, perpetuating an
inﬂammatory state. This occurs in patients with metabolic
syndrome, type II diabetes, and cardiovascular disease. In
addition, low plasma adiponectin has been associated with
myocardialinfarctioninyoungpatientsindependentofother
conventional risk factors [29]. Of interest, in diseases that
are not necessarily related to obesity, adiponectin levels have
recently been shown to be increased in chronic inﬂam-
m a t o r ya n da u t o i m m u n ed i s e a s e ss u c ha st y p eId i a b e t e s ,
SLE, rheumatoid arthritis, inﬂammatory bowel disease, and
chronic systolic heart failure. The latter is contrary to the
decrease in adiponectin levels in heart failure related to
obesity [30]. Adiponectin levels are also increased in human
patients with hypertrophic cardiomyopathy associated with
diastolic dysfunction [31].
In this review, we will discuss the various conditions in
which levels of adiponectin are known to be dysregulated
and the impact that these scenarios of inﬂammation have
on disease progression, in particular, the impact on the
cardiovascular system (Figure 1).
3. CardiacRemodeling, Hypertension,and
HeartFailure
Hypertension is associated with left ventricular hypertrophy
which can eventually lead to heart failure. In a mouse model
of transverse aortic constriction, adiponectin deﬁciency
results in concentric left ventricular hypertrophy and greater
mortality at a short-time point; however, when the time
course is extended, the results are limited to the prevention
of left ventricular remodeling and preserved mitochondrial
oxidative capacity [17, 32]. Consistent with this remodeling
data, pioglitazone—a known modulator of inﬂamation and
an activator or adiponectin—reduced cardiac hypertrophy
and ﬁbrosis in wild-type mice subjected to angiotensin-
II-infusion. These beneﬁcial eﬀects were lost when the
same injury and treatment were performed on adiponectin-
deﬁcient mice [33]. When adiponectin-deﬁcient mice are
maintained on a high-fat/high-sucrose/high-salt diet, the
mice become obese, insulin resistant, and hypertensive [34].
In the KKAy mouse, a murine model to study metabolic
syndrome [35, 36], adiponectin administration improved
hypertension [21]. Antihypertensive drugs were used to
determine adiponectin production in vitro, and it was found
that there are varying degrees of adiponectin secretion which
mayimpacttheresultsofthedrugeﬃcacy[37]. With regards
to human studies, signiﬁcantly lower levels of adiponectin
have been found in patients with essential hypertension
compared to normotensive controls [38]. Taken together,
these data suggest that adiponectin plays an important
protective role in the development of hypertension.
While these animal models of heart failure have shown
that adiponectin protects against the development of systolic
dysfunction, adiponectin levels are increased in humans and
may be predictive for mortality, in patients with chronic
heart failure [39]. The exact cause of the upregulation is
unknown, but several hypotheses are likely. First, it is
possible that increased expression of adiponectin may be a
compensatory response to the stress of heart failure, similar
to the mechanism described for B-type natriuretic peptide
(BNP) secretion [40]. Although the molecular mechanisms
are unknown, BNP levels correlate with adiponectin levels
in human heart failure [39, 40]. Furthermore, direct stim-
ulation of human adipocytes with BNP has been shown to
result in a cGMP-dependent release of adiponectin [41]. A
second possibility for elevated adiponectin levels in cardiac
disease could be the development of a condition termed
“adiponectin resistance.” Although the mechanism has not
been elucidated, adiponectin resistance has been described
in a small number of published studies in both human tissue
and animal models [42–44]. Furthermore, as observed in
systolic heart failure, increased levels of adiponectin may
result as a compensatory response to aberrant expression
of adiponectin receptors. Therefore, disrupted adiponectin
signaling in target tissues (resulting from a change in
adiponectin receptor expression) may act as a compensatory
response and partially explain the observed increase in
adiponectin levels in these disease states.
4.CoronaryArteryDisease
The relationship between adiponectin levels and coronary
artery disease and acute coronary syndrome is not so
straightforward. There is an inverse relationship between
serum adiponectin levels and nondiabetic patients with
regardtotheseverityofcoronaryarterydisease.IntypeIdia-
betic patients and nondiabetic controls, hypoadiponectine-
mia is associated with coronary artery calciﬁcation [45]. InInternational Journal of Inﬂammation 3
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Figure 1: Adiponectin levels and inﬂammatory state. In healthy individuals, adiponectin maintains anti-inﬂammatory properties. Disease
states where adiponectin levels decrease result in proinﬂammatory signaling and exacerbation of disease. Recent data has shown that
adiponectin levels are increased in chronic inﬂammatory diseases, but the reason for this is incompletely understood.
addition,adiponectinlevelsaresigniﬁcantlylowerinpatients
with acute coronary syndrome compared to patients with
stable angina and healthy controls [46]. Furthermore, the
development of atherosclerosis and coronary artery disease
goes hand in hand. Adiponectin has anti-atherosclerotic,
as well as anti-inﬂammatory properties that may play an
important role in preventing the progression of coronary
artery disease. Results from clinical surveys show that low
adiponectin levels, while being a predictive marker for early-
stage atherosclerosis, are also signiﬁcantly associated with
coronary artery disease [3].
5. Accelerated Atherosclerosis and Lupus
Accelerated atherosclerosis is believed to be a critical factor
contributing to stroke and coronary heart disease (CHD), a
leading cause of death among young women with SLE. Clin-
ical studies have largely examined the relation between SLE
and endpoint cardiac events including myocardial infarction
and stroke [47, 48]. More recently, attention has shifted
towards the causes of advanced cardiovascular diseases,
the focus now being on the contribution of accelerated
atherosclerosis in SLE patients. To complicate matters, it has
beenshownthatthereisanincreasedincidenceofaccelerated
atherosclerosis, and as a result, increased endpoint cardiac
events in patients with SLE. The exact cause is unknown, but
chronic inﬂammation is likely a contributing factor.
Adiponectin plays a role in the inﬂammatory compo-
nents of cardiovascular diseases. To begin with, lack of
adiponectin in a mouse model of atherosclerosis leads to not
only an increase in T-cell accumulation within the lesions,
but also an increase in total atherosclerotic lesion area com-
pared to adiponectin-suﬃcient controls [49]. Adiponectin is
also known to be upregulated by PPARγ and treatment with
PPARγ agonists results in decreased atherosclerosis [50]. A
meta-analysis of studies to determine the renal protective
eﬀects of PPARγ agonists on diabetic patients showed that
urine albumin excretion was decreased in patients receiving
PPARγ agonists [51]. Based on this information, our lab
hypothesized that the several immunomodulatory eﬀects of
PPARγ agonists could potentially be beneﬁcial in lupus since
glomerulonephritis is a major complication of lupus. Induc-
ing adiponectin upregulation by maintaining two diﬀerent
mouse models on a PPARγ agonist-containing diet resulted
in signiﬁcantly less disease than mice receiving vehicle treat-
ment. We further showed that these eﬀects were mediated by
adiponectin [52]. These data suggest that the increased level
of adiponectin derived from upregulation by PPARγ plays a
major role in the decrease of inﬂammation in these models.
Other studies have utilized mouse models to further
elucidate the interaction between atherosclerosis and lupus.
Several diﬀerent lupus-like mouse models, including gld, lpr,
and Sle1.2.3, have been used in the generation of various
chimeras with either apoE−/− or LDLr−/− mice, which are
prone to atherosclerosis. These models consistently report
that lupus disease and vascular complications are worsened
whensimultaneouslypresent,withinﬂammationlikelybeing
a contributing factor [53–56]. The involvement of adi-
ponectin has not been examined in these models; however,
given the importance of this adipokine in regulating SLE as
well as inﬂammatory processes involved in atherosclerosis,
it would be of great interest to study not only the levels of4 International Journal of Inﬂammation
adiponectin, but also to administer exogenous adiponectin
to determine if the phenotypes could be rescued.
6. PulmonaryDisease and
Pulmonary Hypertension
Cardiopulmonary complications are widely recognized
causes of morbidity and mortality especially in obese
adults [57]. Several instances have been described where
adiponectin (or lack thereof) is involved in the progression
of the disease. The presence of adiponectin in lung was ﬁrst
described by Summer et al. In this study, the authors show
that alveolar macrophages from mice lacking adiponectin
spontaneously produce increased levels of TNFα in vitro.
In addition, these mice have increased expression of proin-
ﬂammatory cytokines and matrix metalloproteinases, and
the lungs display an emphysema-like phenotype including
dilated air spaces, decreased tissue elastance, and increased
lung displacement volume [58]. The same group has shown
that adiponectin is found on the luminal side of the lung
blood vessels and serves to inhibit TNFα-induced upregula-
tion of E-selectin which is expressed when endothelial cells
become inﬂamed. There was also evidence of pulmonary
hypertension associated with the inﬁltration of perivascular
inﬂammatory cells in an adiponectin-deﬁcient mouse model
[59]. In a similar vein, allergic airway inﬂammation, a model
of chronic asthma, induced in adiponectin-deﬁcient mice
resulted in pulmonary vascular remodeling and pulmonary
arterial hypertension [60]. Overexpression of adiponectin
has direct eﬀects on pulmonary artery smooth muscle cells
in a murine model of inﬂammation-induced pulmonary
hypertension. The result was reduced disease and improved
pulmonary arterial remodeling [61]. Similarly, hypoxia-
induced pulmonary arterial remodeling and right ventric-
ular hypertrophy can be attenuated by overexpression of
adiponectin [62]. More recently, it has been shown that
patients with higher levels of plasma adiponectin after acute
respiratory failure have a higher risk of mortality. Analysis of
serum adiponectin at day 1 or day 6 after respiratory failure
showed that low levels of adiponectin at the earlier timepoint
were associated with increased survival [63]. Further study
is required to explain the diﬀerent results observed between
humanandanimalstudies.Itispossiblethat,inhumanswith
an acute illness, the increased levels of adiponectin could be
a compensatory response or could be a result of resistance
with relation to adiponectin receptors. Taken together, the
mouse and human data suggest that adiponectin plays a role
in pulmonary disorders and may play a role in modulating
the acute response to critically ill patients, which is an area of
research that should be further studied.
7. Angiogenesis
Prior data from our lab and others has shown that
adiponectin modulates angiogenesis in vitro and in vivo.
This has been demonstrated using mouse models of tissue
ischemia and cardiac remodeling as well as rabbit corneal
models of angiogenesis [20, 64, 65]. For example, pre-
treatment with adiponectin of endothelial progenitor cells
for angiogenic cell therapy results in enhanced survival and
proliferation of the cells in an ischemic hind-limb model,
suggesting that high levels of adiponectin are essential for a
robust angiogenic response [66]. Furthermore, adiponectin-
deﬁcient mice have a poor angiogenic response to ischemic
hind-limb surgery; however, the systemic administration of
adiponectin restores the angiogenic response to that seen in
wild-type controls [20] .Am o u s em o d e lo fc a r d i a cs p e c i ﬁ c
angiogenesis, transverse aortic constriction was performed
in both adiponectin-deﬁcient and wild-type mice, and a
reduction in capillary density was observed as well as an
increase in LVH, pulmonary congestion, and a reduction in
LV systolic function in the mice lacking adiponectin. Once
again, these data suggest that adiponectin is involved in
angiogenesis related to cardiac remodeling [65]. One mech-
anistic explanation for the beneﬁcial eﬀects of adiponectin
in angiogenesis has been demonstrated to occur through
AMPK-dependent regulation. Another branch of the angio-
genic regulatory pathway is implicated by in vitro and in
vivo data linking adiponectin to a positive revascularization
response to ischemia via COX-2 signaling which is known to
be vasculo-protective [67]. Adiponectin supplementation to
wild-type mice also resulted in an increased rate of recovery
with regard to limb perfusion. Thus, adiponectin is able
to act in several ways to promote a favorable angiogenic
response.
8.Obesity,Vascularity,andAngiogenesis
Given its relationship to cardiovascular complications and
the clinical importance of obesity in the United States, it is
somewhat surprising that only recently has the importance
of adipose tissue microenvironment been addressed in
molecular studies related to metabolic dysfunction. Both
animal models and obese human studies demonstrate that
total fat mass does not necessarily provide an indicator for
metabolic status. These types of studies have led to the
thought that metabolic dysfunction is not related to the
adipose tissue quantity alone, but rather, the quality of the
individual adipocyte [28]. The factors contributing to the
characteristics of the adipocyte in this context are likely
relatedtothestatusoffatpadinﬂammationanditsperfusion
by the microvessels. It is possible that reducing the blood
ﬂow in the adipose tissue may result in spontaneous necrosis
of the large adipocytes that are present in obese states,
and this will contribute to inﬂammation. Numerous studies
have shown that adiponectin deﬁciency leads to diminished
tissueperfusionandthatelevatedadiponectinlevelspromote
vascular growth in skeletal muscle and tumor vascularity.
However, to date, there are no studies that have examined
the role of adiponectin in adipose tissue perfusion. Capillary
rarefaction in the fat pads has been observed in obese mice,
and this has also been correlated with a decrease in the
expression of the angiogenic growth factor VEGF, which
can lead to adipose tissue hypoxia [68, 69]. This blood
ﬂow restriction in the adipose tissue could contribute to theInternational Journal of Inﬂammation 5
propagation of the inﬂammation. Recent studies have begun
to determine the impact of fat pad expansion on adipose
tissue hypoxia and capillary density in mouse models and
humans.Ithasbeensuggestedthatspontaneous necrosiswill
occur in larger-sized adipocytes as a result of the limited
oxygen from the circulation. Thus, there is a recruitment of
macrophages to the adipose tissue in order to phagocytose
the dying cells. It is possible that adiponectin, since it has a
major role in both cardio-protective and anti-inﬂammatory
processes, also plays a role in adipose tissue vascularity and
inﬂammation.
9. Macrophage Phenotypeand Obesity
Macrophages found in the adipose tissue contribute greatly
toobesity-relatedmetabolicdysfunctionandchronicinﬂam-
mation [69] .Ac o r r e l a t i o nh a sb e e nm a d ei nb o t hh u m a n s
and animal models showing that macrophage inﬁltration
leads to the development of insulin resistance [12, 70, 71].
The accumulation of “crown-like” structures, which are
markers of “inﬂamed fat”, suggests that clearance of dead
adipocytes by macrophages is impaired, and this may be due
to dysregulated adipokine levels or another obesity-related
factor [72].
Macrophages can be characterized as M1 or M2 depend-
ing on their activation phenotype, which is similar to
Th1/Th2 polarization. “Classically activated” macrophages
are referred to as having an M1 phenotype and can up-
regulate cytokines generally involved in pro-inﬂammatory
p r o c e s s e ss u c ha sT N F α, IL-6, and IL-12. In addition, M1-
type macrophages can increase the production of reactive
oxygen species and nitrogen intermediates. “Alternatively
activated” macrophages are categorized as having an M2
phenotype. These macrophages secrete IL-10, which is an
anti-inﬂammatorycytokineandpartakemostlyinthedown-
regulation of pro-inﬂammatory cytokines. M2 macrophages
canalsoupregulatearginase-1whichhastheabilitytodimin-
ish the inducible nitric oxide synthase reaction. Other func-
tions of M2 macrophages include the ability to upregulate
scavenger receptors, mannose receptors, and the IL-1 recep-
tor antagonist [73–75]. Characterization of macrophages
from adipose tissue shows diﬀerential activation phenotypes
dependent on obesity. Diet-induced obesity in a mouse
model results in adipose tissue macrophages that have an
M1-type phenotype. However, in lean mice, macrophages
express markers of the M2 phenotype suggesting a switch
from an anti-inﬂammatory phenotype to a more pro-
inﬂammatory phenotype [76]. Therefore, it is reasonable to
suggest that diet-induced obesity is capable of shifting the
activationcharacteristicsofmacrophagesfromtheprotective
M2-phenotype, to the pro-inﬂammatory state leading to
metabolic dysfunction characterized by the M1-phenotype.
Analysis of peritoneal macrophages and the stromal
vascular fraction of cells from adipose tissue of adiponectin-
deﬁcient mice reveals a shift towards increased expression
of cytokines related to macrophages with an M1-type pro-
inﬂammatory phenotype. In contrast, exogenous overex-
pression of adiponectin can decrease the generation of
reactive oxygen species, while also shifting the macrophage
population to those of an M2-type phenotype [77].
Taken together, it is interesting to speculate that the
power of adiponectin in shifting inﬂammatory properties
of macrophages within adipose tissue combined with the
datathatadiponectin-deﬁcientmiceareunabletoadequately
respond to an ischemic event may be important in the role
of the microenvironment of adipose tissue with relation to
metabolic consequences and the progression of cardiovascu-
lar diseases.
10.Apoptotic CellClearance
Adiponectin is structurally similar to complement C1q,
which is known for its role in the complement cascade
and its ability to bind apoptotic bodies and facilitate their
removal via a non-inﬂammatory process of phagocytosis by
macrophage. C1q belongs to the family of collectin proteins
and among their many anti-inﬂammatory functions, a
major role is to facilitate clearance of apoptotic cells, thus,
maintaining a quiescent, anti-inﬂammatory state. It was
shown in vitro that adiponectin can similarly facilitate the
clearance of apoptotic bodies via calreticulin receptor on
macrophages, resulting in a “quiet” phagocytosis [78]. To
further corroborate these ﬁndings in vivo [79], exacerbation
of the lupus phenotype was observed in a lupus-prone
mouse model lacking adiponectin, and this was shown to
be partially due to impaired clearance of apoptotic material.
Taken together, these data provide evidence that adiponectin
can facilitate a non-inﬂammatory removal of apoptotic
bodies. To extend these ﬁndings to another pathological
condition, serum adiponectin levels are reported to decrease
in patients with early loosening of hip replacement [80]. The
authors hypothesize that decreased clearance of apoptotic
cell remnants due to low adiponectin may contribute to the
degeneration of the hip replacement; however, this is an
area that is currently under investigation. These data provide
further evidence that adiponectin could play a major role
in both apoptotic cell clearance as well as bone destruc-
tion/creation.
With respect to obesity, the observation of “crown-
like” structures (CLS) in adipose tissue is evidence of pro-
inﬂammatory occurrences in obese subjects and animals [72,
81].TheseCLSareringsofmacrophagesusuallysurrounding
an adipocyte and could be the result of a lack of anti-
inﬂammatory adipokines or the inability of macrophages
to clear dead adipocytes, both of which are associated with
obesity. Under normal conditions, clearance of early apop-
totic cells is a non-inﬂammatory process. However, under
obese conditions, the constant accumulation of dying
adipocytes could be sensed by the macrophages to promote
a proinﬂammatory response and, therefore, aggravate the
inﬂammation. This impaired clearance of apoptotic cells in
obesity is of particular interest since the lack of adiponectin
could potentially play a role in driving inﬂammation
resulting from the accumulation of CLS in obesity-related
inﬂammation.6 International Journal of Inﬂammation
11. Concluding Statements
Adiponectin is a highly circulating adipokine that maintains
its anti-inﬂammatory protective eﬀects. Research continues
to show its diverse functions in various disease states. It will
be imperative to clarify the role of adiponectin in cardiovas-
cular disease with relation to inﬂammation. This is compli-
cated by the fact that low levels of adiponectin occur in obe-
sity, type II diabetes, and metabolic disorders, whereas high
levels of adiponectin are found in heart failure and hyperten-
sion, as well as chronic inﬂammatory autoimmune diseases
such as SLE, type I diabetes, and rheumatoid arthritis.
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